Strs Ohio Has $70.46 Million Stake in CVS Health Corporation $CVS

Key Points

• Strs Ohio cut its CVS stake by 14.9% in Q4, selling 155,430 shares and now holds 887,820 shares worth $70.46 million (about 0.07% of the company), while institutional investors own roughly 80.66% of CVS.
• CVS beat Q4 estimates, reporting $1.09 EPS versus $1.00 expected and $105.69 billion in revenue (up 8.2% YoY); management set FY2026 guidance of $5.94–$6.14 EPS and analysts forecast about $7.14 for the current year.
• The company declared a quarterly dividend of $0.665 (annualized $2.66) for a 3.2% yield but with a high payout ratio of 192.75%, and the stock carries a consensus "Moderate Buy" rating with a $95.05 price target.

Strs Ohio decreased its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 14.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 887,820 shares of the pharmacy operator's stock after selling 155,430 shares during the quarter. Strs Ohio owned approximately 0.07% of CVS Health worth $70,457,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its holdings in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock worth $26,000 after purchasing an additional 281 shares during the last quarter. Corundum Trust Company INC bought a new stake in CVS Health during the third quarter worth $29,000. Ares Financial Consulting LLC bought a new stake in CVS Health during the fourth quarter worth $29,000. GoalVest Advisory LLC bought a new stake in CVS Health during the fourth quarter worth $32,000. Finally, SOA Wealth Advisors LLC. raised its position in CVS Health by 36.9% during the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator's stock worth $37,000 after acquiring an additional 131 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Price Performance

Shares of CVS opened at $82.12 on Friday. The firm has a market capitalization of $105.24 billion, a PE ratio of 59.51, a PEG ratio of 0.87 and a beta of 0.60. The company's 50-day moving average is $76.32 and its 200-day moving average is $77.97. CVS Health Corporation has a fifty-two week low of $58.35 and a fifty-two week high of $85.15. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. During the same period in the prior year, the firm earned $1.19 earnings per share. The company's revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities analysts forecast that CVS Health Corporation will post 7.14 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be paid a $0.665 dividend. The ex-dividend date is Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. CVS Health's dividend payout ratio is 192.75%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Regulatory tailwinds for Aetna and clearer PBM policy raised upside visibility for CVS’s Health Services and PBM businesses, boosting investor optimism about Medicare Advantage payments and reduced insulin‑pricing uncertainty. Regulatory Tailwinds Article
• Positive Sentiment: Operational efficiency gains from automation: WSJ reports on CVS’s new highly automated distribution center using robots to move millions of items with far fewer staff — a potential long‑term margin lever. Robotics/Operations Article
• Positive Sentiment: Competitive positioning: coverage notes CVS is pushing health‑services expansion while Walgreens pulls back, which could support share gains in higher‑margin care services. Competitive Positioning Article
• Neutral Sentiment: Earnings preview / analyst focus: Wall Street is parsing Q1 metrics (revenue, pharmacy trends and Health Services growth). Investors are waiting for the company’s March‑quarter results and management color before re‑rating shares. Earnings Countdown Article
• Negative Sentiment: Near‑term margin risk: earnings previews caution that benefits segment pressures and elevated costs could weigh on Q1 results, a key reason investors are cautious ahead of the print. Earnings Preview Article
• Negative Sentiment: Market dynamics and valuation: after a strong run-up, the stock’s rich near‑term multiples and lighter intraday volume can amplify down‑moves as investors lock in gains while awaiting Q1 clarity (contributing to today’s pullback).

Wall Street Analysts Forecast Growth

Several analysts have issued reports on CVS shares. Sanford C. Bernstein raised shares of CVS Health from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $91.00 to $94.00 in a research report on Thursday, March 12th. The Goldman Sachs Group upped their price target on shares of CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a research report on Thursday, February 12th. Wolfe Research dropped their price target on shares of CVS Health from $100.00 to $97.00 and set an "outperform" rating on the stock in a research report on Monday, March 2nd. TD Cowen reaffirmed a "buy" rating on shares of CVS Health in a research report on Friday, March 13th. Finally, Leerink Partners reaffirmed an "outperform" rating and set a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Twenty equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $95.05.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.